Aprea Therapeutics (NASDAQ:APRE) Rating Increased to Hold at Zacks Research

Aprea Therapeutics (NASDAQ:APRE) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Monday,Zacks.com reports.

A number of other brokerages have also issued reports on APRE. Wedbush cut their target price on Aprea Therapeutics from $11.00 to $7.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Wednesday, January 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective (down from $5.00) on shares of Aprea Therapeutics in a research note on Thursday, January 29th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $5.50.

Aprea Therapeutics Stock Performance

Aprea Therapeutics stock opened at $0.60 on Monday. The firm has a market cap of $4.19 million, a price-to-earnings ratio of -0.28 and a beta of 1.48. Aprea Therapeutics has a 1 year low of $0.55 and a 1 year high of $3.72. The firm’s 50 day moving average price is $0.83 and its two-hundred day moving average price is $1.22.

Insider Buying and Selling

In other Aprea Therapeutics news, Director Marc Duey bought 21,459 shares of the company’s stock in a transaction dated Wednesday, December 10th. The shares were bought at an average price of $1.17 per share, for a total transaction of $25,107.03. Following the acquisition, the director directly owned 256,155 shares of the company’s stock, valued at approximately $299,701.35. This trade represents a 9.14% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 13.63% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aprea Therapeutics stock. DRW Securities LLC purchased a new stake in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 120,651 shares of the company’s stock, valued at approximately $103,000. DRW Securities LLC owned about 1.73% of Aprea Therapeutics at the end of the most recent reporting period. Institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.